GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 2-Year Follow-Up of REFLECT Phase III Trial

GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US

GenSight Biologics to Host Key Opinion Leader Webcast on Outcomes Among Compassionate Use Patients Treated Bilaterally with LUMEVOQ® in the US

GenSight Biologics Announces Extension of Day 120 Clock Stop of LUMEVOQ® EMA Regulatory Filing; MAA Review to Resume in April 2022

Cell UK by Oxford’s Global, London (UK) & Virtual

BIO-Europe 2021, Virtual

Mitochondrial Diseases Conference 2021 by Mitocon, Virtual

28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Virtual

2021 ARM Cell & Gene Meeting on the Mesa, Carlsbad, CA (USA) & Virtual